SCRI partners with Yale to advance cancer research

The Yale Cancer Center and Sarah Cannon Research Institute (SCRI) have finalized a deal that would allow the strategic research organization to work with the NCI-designated cancer facility and Smilow Cancer Hospital at Yale-New Haven in advancing cancer research.

The partnership will have physician scientists from SCRI and Yale Cancer Center working together to develop protocols for clinical research and strategic scientific priorities. The deal will also result in the eventual opening of a clinical trial management office at the Yale Cancer Center campus, giving Smilow Cancer Hospital the chance to jump on board by developing its own network of community-based sites to participate in the program. All that will help pave the way for assisting the Ivy League school in starting more research studies, according to an SCRI statement.

"This collaboration allows top scientific thought leaders in cancer to come together to develop enhanced clinical trial opportunities and increase access for patients to the latest treatments available," said Howard "Skip" Burris, chief medical officer and executive director of drug development for SCRI, in a statement.

- see the release

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.